You have matched to 18 trials

Guest Profile:  No profile selected

Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Molecular Profiling to Select Treatment for Advanced Breast Cancer

Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection (STRATA)

Purpose: To conduct a test of your tumor to determine if there are approved therapies or clinical trials targeting the mutations or biomarkers found in your tumor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> Molecular profiling will be done on your tumor sample at no cost.</p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A sample of your tumor will be tested for certain mutations and biomarkers. </li> <li class="seamTextUnorderedListItem">Your doctor will be told if there are treatments or clinical trials available for people with the mutations or biomarkers found in your tumor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03061305' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/broad-molecular-profiling-tests' target='_blank'>Breastcancer.org: Broad Molecular Profiling Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/research/octr/our-research/strata-trial' target='_blank'>UNC Lineberger Comprehensive Cancer Center: Study website</a> </li></ul>
1

Molecular Profiling to Select Treatment for Advanced Breast Cancer

Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection (STRATA)
Icon

Nearest Location:
28 miles
Kaiser Permanente - Northern California
Vallejo, CA

Icon

Visits:
Please contact research site

Icon

ClinicalTrials.gov: NCT03061305

Icon

Phase NA

2

PET/CT Scan to Determine Next Treatment for Metastatic ER+, HER2- Breast Cancer

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy

Purpose: To study whether a PET/CT scan with 18F FES helps your doctor choose your next treatment.

Who is this for?: Women with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low breast cancer that progressed after their first line of hormone therapy for metastatic disease. You must not have received more than 1 line of chemotherapy for metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fluoroestradiol F18 (18F FES, Cerianna™), by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaire, 3 times within 1.5 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your doctor will use the results of your PET/CT scan to determine your next treatment.</li> <li class="seamTextUnorderedListItem">Fluoroestradiol F18 (18F FES, Cerianna™) is a tracer that is used to visualize the estrogen receptor (expressed by some cancer cells) during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer to look for signs of disease, including cancer.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ and 2+.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05068726' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gehealthcare.com/products/nuclear-imaging-agents/cerianna' target='_blank'>GE Healthcare: Fluoroestradiol F18 (18F FES, Cerianna™)</a> </li></ul>
2

PET/CT Scan to Determine Next Treatment for Metastatic ER+, HER2- Breast Cancer

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy
Icon

Nearest Location:
40 miles
PET/CT Imaging of San Jose
San Jose, CA

Icon

Visits:
1 day

Icon

ClinicalTrials.gov: NCT05068726

Icon

Phase NA

3

Biopsy to Select Treatment for Metastatic HER2-Negative Breast Cancer

FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial

Purpose: To study the ability of genomic testing and drug screening of tumor tissue to select your next treatment(s).

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer. If your cancer is triple negative (ER, PR-, HER2-), you must not have received treatment for metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy to collect tumor tissue</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor tissue collected during the biopsy will be used for genomic testing and drug screening.</li> <li class="seamTextUnorderedListItem">Genomic testing identifies DNA in your tumor cells.</li> <li class="seamTextUnorderedListItem">Drug screening tests the response of your tumor cells to potential treatments.</li> <li class="seamTextUnorderedListItem">The results from the genomic testing and drug screening may be used by your doctor to choose your next treatment(s).</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04450706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancercenter.com/treatment-options/precision-medicine/advanced-genomic-testing' target='_blank'>Cancer Treatment Centers of America: Genomic Testing</a> </li></ul>
3

Biopsy to Select Treatment for Metastatic HER2-Negative Breast Cancer

FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial
Icon

Nearest Location:
602 miles
Huntsman Cancer Institute at University of Utah
Salt Lake City, UT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04450706

Icon

Phase NA

4

Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer

Purpose: To study whether the CELLSEARCH® Circulating Tumor Cell Test helps doctors make treatment decisions and determine response to treatment.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or triple negative (ER-, PR-, HER2-) breast cancer. If you have ER+, HER2- breast cancer, you must have received at least 1 line of therapy for metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample for CELLSEARCH® Circulating Tumor Cell Test</li> </ul> <p class="seamTextPara"> followed within 1.5 years by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging scans, at least 1 time</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">The CELLSEARCH® Circulating Tumor Cell Test can detect CTCs in your blood to help your doctor make treatment decisions and determine your response to treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05662345' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cellsearchctc.com/about-cellsearch/what-is-cellsearch-ctc-test' target='_blank'>Menarini Silicon Biosystems: CELLSEARCH® Circulating Tumor Cell Test</a> </li></ul>
4

Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer
Icon

Nearest Location:
1539 miles
Mayo Clinic Health System Mankato
Mankato, MN

Icon

Visits:
At least 2 visits

Icon

ClinicalTrials.gov: NCT05662345

Icon

Phase NA

5

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)

Purpose: To study if radiation therapy can delay treatment changes and if circulating tumor cells (CTCs) can help guide treatment options.

Who is this for?: Women with stage IV (metastatic) breast cancer who have been receiving their first line of therapy for metastatic disease for at least 1 year or have been receiving their second or later line of therapy for at least 6 months. You must have 1-3 sites of oligoprogressive disease that have not received radiation and must not have triple negative breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation (also called stereotactic radiosurgery or stereotactic body radiotherapy) delivers high-dose, precisely-targeted radiation in fewer doses than traditional radiation therapy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">In this trial, CTCs may be used to help you and your doctor guide treatment options.</li> <li class="seamTextUnorderedListItem">Oligoprogressive disease refers to progression of only a few sites of metastasis.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06055881' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20555625' target='_blank'>Mayo Clinic: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/sbrt/pyc-20446794' target='_blank'>Mayo Clinic: Stereotactic Body Radiotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20071218' target='_blank'>Breastcancer.org: Circulating Tumor Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/oligometastatic-breast-cancer/' target='_blank'>Metastatic Trial Talk: What is Oligometastatic Breast Cancer?</a> </li></ul>
5

Radiation to Delay Treatment Changes and CTCs to Guide Treatment Options for People with Metastatic Breast Cancer

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)
Icon

Nearest Location:
1615 miles
Mayo Clinic in Rochester
Rochester, MN

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06055881

Icon

Phase NA

6

Safely Stopping Anti-HER2 Targeted Therapy for People with Advanced HER2+ Breast Cancer Who Are Exceptional Responders

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer

Purpose: To study if anti-HER2 targeted therapy can be safely stopped in people with HER2 positive metastatic breast cancer that have had an exceptional response to treatment.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer that has not progressed in the last 3 years during treatment with any anti-HER2 targeted therapy as a first line of therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You can choose to participate in 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Choose to Continue Anti-HER2 Treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Continue anti-HER2 treatment</li> <li class="seamTextUnorderedListItem">Visits, monthly for 2-3 months, then every 3 months</li> <li class="seamTextUnorderedListItem">Imaging scans, every 3 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Choose to Stop Anti-HER2 Treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop anti-HER2 treatment</li> <li class="seamTextUnorderedListItem">Visits, monthly for 2-3 months, then every 3 months</li> <li class="seamTextUnorderedListItem">Imaging scans, every 3 months</li> </ul> <p class="seamTextPara"> followed 1 year later by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stop treatment indefinitely if no progression</li> <li class="seamTextUnorderedListItem">Imaging scans (surveillance), every 3-6 months for 10 years</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You can choose which group you would like to participate in.</li> <li class="seamTextUnorderedListItem">Exceptional response is considered cancer progression being controlled for 3 years or more since starting anti-HER2 targeted treatment.</li> <li class="seamTextUnorderedListItem">This study is also studying whether blood samples that may contain traces of DNA from cancer, known as circulating tumor DNA (ctDNA), are able to help identify which people can successfully stop treatment without a change in their cancer.</li> <li class="seamTextUnorderedListItem">If you have estrogen receptor positive (ER+) breast cancer, you will continue hormone therapy.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05721248' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/clinical-trials2/detail/22-655/' target='_blank'>Dana-Farber Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/mbc-exceptional-responder/' target='_blank'>Metastatic Trial Talk: Why Do Some People Have an Exceptional Response When Being Treated for MBC?</a> </li></ul>
6

Safely Stopping Anti-HER2 Targeted Therapy for People with Advanced HER2+ Breast Cancer Who Are Exceptional Responders

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
Icon

Nearest Location:
1643 miles
Baylor College of Medicine
Houston, TX

Icon

Visits:
1 visit every 3 months

Icon

ClinicalTrials.gov: NCT05721248

Icon

Phase II

7

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT

Purpose: To evaluate prostate specific membrane antigen (PSMA) expression in breast cancer to determine people most likely to benefit from anti-androgen therapies.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-), androgen receptor positive (AR+) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>
7

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT
Icon

Nearest Location:
1761 miles
University of Wisconsin School of Medicine and Public Health
Madison, WI

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04573231

Icon

Phase II

8

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Purpose: To collect information to develop a Guardant360 blood test that can measure treatment response.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) who have received 0-1 lines of therapy for advanced disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 blood test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Guardant360 is a blood test that identifies genomic biomarkers and mutations to help make treatment decisions.</li> <li class="seamTextUnorderedListItem">This trial is collecting information to develop a future version of Guardant360 that can measure treatment response.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05935384' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/tumor-marker-tests' target='_blank'>Breastcancer.org: Breast Cancer Biomarkers and Biomarker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/' target='_blank'>Guardant Health: Guardant360 Test Information Page</a> </li></ul>
8

Guardant360 Blood Test to Measure Treatment Response for People with Advanced Breast Cancer

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Icon

Nearest Location:
1849 miles
Orchard Healthcare Research Inc.
Skokie, IL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05935384

Icon

Phase NA

9

Pharmacogenomics Testing to Make Chemotherapy Dosing Decisions for People with Breast Cancer

PhOCus: Implementation of Pharmacogenomic Testing in Oncology Care

Purpose: To study if pharmacogenomics testing, a type of genetic testing, helps doctors make chemotherapy dosing decisions and decreases chemotherapy side effects.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive chemotherapy. You must be receiving care at The University of Chicago Medical Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive chemotherapy</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide DNA samples for pharmacogenomics testing, after chemotherapy treatment</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide DNA samples for pharmacogenomics testing</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive chemotherapy based on pharmacogenomics testing results</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Doctors leading the study will collect your genetic information using pharmacogenomics/genotyping, a type of genetic testing.</li> <li class="seamTextUnorderedListItem">Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications.</li> <li class="seamTextUnorderedListItem">If you are in Group 2, your doctor will use your test results to make dosing decisions/changes to your chemotherapy treatment.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04541381' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://nigms.nih.gov/education/fact-sheets/Pages/pharmacogenomics.aspx#:~:text=Pharmacogenomics%20(sometimes%20called%20pharmacogenetics)%20is,best%20suited%20for%20each%20person.' target='_blank'>National Institutes of Health: Pharmacogenomics</a> </li></ul>
9

Pharmacogenomics Testing to Make Chemotherapy Dosing Decisions for People with Breast Cancer

PhOCus: Implementation of Pharmacogenomic Testing in Oncology Care
Icon

Nearest Location:
1857 miles
University of Chicago Medical Center
Chicago, IL

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04541381

Icon

Phase NA

10

OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine

Purpose: To study the ability of the OmniSeq Test to detect biomarkers and mutations compared to a liquid biopsy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and/or tissue samples for OmniSeq Test</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The OmniSeq Test is a genomic test that detects biomarkers and mutations for many types of cancer.</li> <li class="seamTextUnorderedListItem">The OmniSeq Test may help your doctor select your treatment based on detected biomarkers and mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05697198' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncology.labcorp.com/cancer-care-team/test-menu/omniseq-insight' target='_blank'>Labcorp: OmniSeq Test</a> </li></ul>
10

OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine
Icon

Nearest Location:
1906 miles
Clinical Site
Covington, LA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05697198

Icon

Phase NA

11

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors

Purpose: To study how breast cancer develops resistance to treatment with CDK 4/6 inhibitors and how to predict response to treatment with CDK 4/6 inhibitors.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or people with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) node positive breast cancer. You must have completed treatment with or currently be receiving treatment with a CDK 4/6 inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood, tissue, fluid, and biopsy samples</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your samples may be used to help your doctor make treatment decisions.</li> <li class="seamTextUnorderedListItem">Node positive breast cancer is breast cancer that has spread to the lymph nodes.</li> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>
11

Studying Response to Treatment With CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
Icon

Nearest Location:
2299 miles
Roswell Park Cancer Institute
Buffalo, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04526587

Icon

Phase NA

12

Tumor Samples From Surgery to Predict Response to Treatment for Brain Metastasis

A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors

Purpose: To study a new way to predict response to treatment using tumor samples from brain surgery.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive brain surgery. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of tumor samples during brain surgery</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will use tumor samples from brain surgery to determine which types of treatments are most likely to be effective.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05978557' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
12

Tumor Samples From Surgery to Predict Response to Treatment for Brain Metastasis

A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors
Icon

Nearest Location:
2378 miles
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Icon

Visits:
Coincides with routine care

Icon

ClinicalTrials.gov: NCT05978557

Icon

Phase NA

13

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer

Purpose: To study if genomic testing affects which line of therapy doctors suggest people with metastatic breast cancer receive.

Who is this for?: People with metastatic (stage IV) breast cancer who have received no more than one line of therapy for metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PAM50 (Prosigna®) testing of your breast tumor, 1 time</li> <li class="seamTextUnorderedListItem">Results of the PAM50 test will be given to your treating doctor</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The standard of care for treating metastatic breast cancer is to make treatment decisions based on clinical subtype. </li> <li class="seamTextUnorderedListItem">Clinical subtypes include hormone-positive (ER+ and/or PR+), HER2-positive (HER2+), and triple-negative (ER-, PR-, HER2-).</li> <li class="seamTextUnorderedListItem">The PAM50 (Prosigna®) is a genomic test approved for use in some women with early-stage breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor. This gives your doctor a genetic subtype of your tumor. </li> <li class="seamTextUnorderedListItem">This trial is studying whether knowing a tumor's genetic subtype will affect how doctors treat people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Making treatment decisions based on genetic subtypes is not the standard of care.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03769415' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/octr/our-team/' target='_blank'>Study Coordinator Information: Terri Eubanks</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/genomic-tumor-testing/' target='_blank'>Metastatic Trial Talk: Genomic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prosigna.com' target='_blank'>Veracyte Test Information Page: PAM50 (Prosigna®)</a> </li></ul>
13

HARMONY: Using a Genomic Test to Guide Treatment Decisions for Metastatic Breast Cancer

HARMONY: Harnessing the Analysis of RNA Expression and Molecular Subtype to Optimize Novel TherapY for Metastatic Breast Cancer
Icon

Nearest Location:
2402 miles
UNC Rex Healthcare
Raleigh, NC

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT03769415

Icon

Phase NA

14

Genetic Testing to Determine Treatment for ER+, HER2- Metastatic Breast Cancer

Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition

Purpose: To study the ability of two types of genetic testing to determine the best treatment.

Who is this for?: People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that received treatment with a CDK 4/6 inhibitor and anastrazole (Arimidex®) or letrozole (Femara®). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">FoundationOne and Fulgent genetic testing</li> <li class="seamTextUnorderedListItem">Drug based on genetic testing results</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">There are several approved treatments for metastatic ER+, HER2- breast cancer. Right now, doctors do not have a good way of choosing between these treatments.</li> <li class="seamTextUnorderedListItem">Researchers have developed a way to predict which treatment is best.</li> <li class="seamTextUnorderedListItem">This study is being done to test if those predictions are right and to learn more about these tumors to design better treatments in the future.</li> <li class="seamTextUnorderedListItem">You will receive a drug based on the results of your genetic testing results.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04965688' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.foundationmedicine.com/info/detail/for-patients' target='_blank'>Foundation Medicine: FoundationOne Genetic Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://fulgentoncology.com/patients' target='_blank'>Fulgent: Genetic Testing</a> </li></ul>
14

Genetic Testing to Determine Treatment for ER+, HER2- Metastatic Breast Cancer

Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
Icon

Nearest Location:
2425 miles
Inova Schar Cancer Institute
Fairfax, VA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT04965688

Icon

Phase II

15

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases

Purpose: To compare how well multi-disciplinary care and standard care work for managing symptoms and understanding outcomes.

Who is this for?: People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Your brain metastases must be newly diagnosed. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Usual care</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Multi-disciplinary care</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Care for people with brain metastases involves complex medical decision making and requires input for multiple groups (disciplines).</li> <li class="seamTextUnorderedListItem">Multi-disciplinary care includes medical oncology, neurosurgery, radiation oncology, neuro-oncology, and palliative care.</li> <li class="seamTextUnorderedListItem">This process may look different for different patients.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06280300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
15

Multi-Disciplinary Care and Decision Making for People with Brain Metastases

Intensive Multi-Disciplinary Care Initiative for Patients With Newly Diagnosed Brain Metastases
Icon

Nearest Location:
2564 miles
University of Vermont Medical Center
Burlington, VT

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06280300

Icon

Phase NA

16

Clinical Trial Education and Navigation for People with Stage I-IV Breast Cancer

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

Purpose: To study whether a list of clinical trials, clinical trial educational materials, and clinical trial patient navigators (CTPN) increase participation in clinical trials, especially in the Black, Indigenous, and People of Color (BIPOC) community.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">List of matched clinical trials</li> <li class="seamTextUnorderedListItem">Clinical trial educational materials</li> <li class="seamTextUnorderedListItem">Clinical trial patient navigator (CTPN)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a list of matched clinical trials and educational materials designed to inform and empower you to consider clinical trials.</li> <li class="seamTextUnorderedListItem">You will also work with a clinical trial patient navigator (CTPN) to further educate you about clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is available in English and Spanish.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05146297' target='_blank'>ClinicalTrials.gov</a> </li></ul>
16

Clinical Trial Education and Navigation for People with Stage I-IV Breast Cancer

Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
Icon

Nearest Location:
2569 miles
Herbert Irving Comprehensive Cancer Care Center
New York, NY

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05146297

Icon

Phase NA

17

Improving Cancer Care and Mental Health Care for People with Newly Diagnosed Stage I-IV Breast Cancer

Adapting the Tumor Board Model for Mental Illness and Cancer: A Single Arm Pilot Trial

Purpose: To study whether a virtual tumor board can improve cancer care and mental health care.

Who is this for?: People with newly diagnosed stage I, stage II, stage III, or stage IV (metastatic) breast cancer. You must also have one of the following mental illnesses: schizophrenia, bipolar disorder, or major depressive disorder. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Assessment of your needs, values, mental health symptoms, and barriers to care</li> <li class="seamTextUnorderedListItem">Recommendations from the virtual tumor board to help you receive the care you need</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tumor board is a group of doctors and other health care providers that meets regularly at the hospital to discuss cancer cases and share knowledge.</li> <li class="seamTextUnorderedListItem">A virtual cancer and mental health tumor board may help people access the cancer and mental health care they need.</li> <li class="seamTextUnorderedListItem">The tumor board will notify your doctor with treatment and care recommendations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05837598' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/blog/2017-07/what-tumor-board-expert-qa' target='_blank'>ASCO: What is a Tumor Board?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mhanational.org/cancer-and-mental-health' target='_blank'>Mental Health America: Cancer and Mental Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/lung-cancer-treating-mental-health-longer-survival' target='_blank'>National Cancer Institute: Study Links Mental Health Treatment to Improved Cancer Survival</a> </li></ul>
17

Improving Cancer Care and Mental Health Care for People with Newly Diagnosed Stage I-IV Breast Cancer

Adapting the Tumor Board Model for Mental Illness and Cancer: A Single Arm Pilot Trial
Icon

Nearest Location:
2698 miles
Mass General/North Shore Center for Outpatient Care
Danvers, MA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05837598

Icon

Phase NA

18

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Purpose: To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>
18

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
No Travel Required
Icon

Visits:
No visits required

Icon

ClinicalTrials.gov: NCT03452774

Icon

Phase NA

HELP GUIDE
HELP GUIDE